Free NAPLEX Practice Test Questions and Answers (2026) | Cert Empire Practice Questions

Lecithin is primarily used in pharmaceutical compounding as an emulsifying agent, surfactant, or wetting agent. Its main function is to stabilize mixtures of oil and water (emulsions). While some components of lecithin may exhibit minor antioxidant properties, it is not classified or utilized as an antimicrobial preservative. The other options are all well-established preservatives used to prevent the growth of bacteria, yeast, and mold in pharmaceutical preparations, thereby ensuring their stability and safety.

A. Benzalkonium chloride is a quaternary ammonium compound widely used as an antimicrobial preservative, particularly in ophthalmic, otic, and nasal preparations.

C. Sodium benzoate is a common preservative used to inhibit the growth of mold and yeast in acidic oral liquid preparations, foods, and cosmetics.

D. Benzyl alcohol is an aromatic alcohol frequently used as a bacteriostatic preservative in multi-dose parenteral (injectable) formulations and topical products.

1. Rowe

R. C.

Sheskey

P. J.

& Quinn

M. E. (Eds.). (2012). Handbook of Pharmaceutical Excipients (7th ed.). Pharmaceutical Press.

Lecithin: "Functional category: Emulsifying agent; emollient; solubilizing agent." (p. 417).

Benzalkonium Chloride: "Functional category: Antimicrobial preservative; antiseptic; disinfectant; solubilizing agent; wetting agent." (p. 56).

Sodium Benzoate: "Functional category: Antimicrobial preservative." (p. 627).

Benzyl Alcohol: "Functional category: Antimicrobial preservative; disinfectant; solvent." (p. 64).

2. Allen

L. V. (2018). Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (11th ed.). Wolters Kluwer.

Chapter 18: Pharmaceutical Excipients: This chapter lists benzalkonium chloride

benzyl alcohol

and benzoic acid/its salts (like sodium benzoate) in the table of "Antimicrobial Preservatives." Lecithin is discussed and categorized under "Emulsifying and Suspending Agents." (Section: "Excipients Used in Liquid Dosage Forms").

3. United States Pharmacopeia and National Formulary (USP-NF). USP Pharmaceutical Dosage Forms.

This general chapter describes the typical components of various dosage forms. Preservatives are defined as substances added to inhibit microbial growth. Emulsifying agents

like lecithin

are defined as substances that promote and maintain the dispersion of one immiscible phase in another.

Systemic corticosteroids, such as dexamethasone, are well-documented to cause a wide range of dose-dependent neuropsychiatric adverse effects. These can range from mild mood changes and insomnia to severe reactions like mania, depression, delirium, and frank psychosis, often termed "steroid psychosis." The symptoms described in the question—emotional lability, hallucinations, mania, and mood swings—are classic manifestations. The patient's high dose of dexamethasone (32 mg/day) and advanced age increase this risk significantly. While other medications listed can cause CNS disturbances, the specific constellation of symptoms, particularly mania and significant mood swings, is most characteristic of corticosteroid therapy.

A. Lisinopril: While mood changes can occur, ACE inhibitors are not commonly associated with causing severe psychotic episodes.

C. Famotidine: Can cause confusion and delirium, especially in elderly patients with renal impairment, but is less likely to induce mania or a full psychotic syndrome.

D. Metoclopramide: Can cause CNS effects like confusion and hallucinations, but is more characteristically associated with extrapyramidal symptoms and tardive dyskinesia.

E. Hydromorphone: Opioids are a common cause of sedation, confusion, and delirium in the elderly, but are less frequently implicated in causing mania or complex mood disorders.

1. DiPiro

J. T.

Yee

G. C.

Posey

L. M.

Haines

S. T.

Nolin

T. D.

& Ellingrod

V. (2020). Pharmacotherapy: A Pathophysiologic Approach (11th ed.). McGraw-Hill. In the chapter on "General Principles of Endocrine Pharmacology

" the adverse effects of glucocorticoids are detailed

including behavioral and personality changes

euphoria

insomnia

and psychosis.

2. Kenna

H. A.

Poon

A. W.

de la Rue

O. P.

& Rasgon

N. L. (2011). Neuropsychiatric effects of corticosteroids: a review. Comprehensive Psychiatry

52(5)

519–528. (See Abstract and Section 3

"Psychiatric Disturbances"). This review states that corticosteroid-induced psychiatric disturbances include mania

depression

psychosis

and delirium

with risk increasing at higher doses (e.g.

>40 mg of prednisone or equivalent per day). https://doi.org/10.1016/j.comppsych.2010.10.004

3. Warrington

T. P.

& Bostwick

J. M. (2006). Psychiatric adverse effects of corticosteroids. Mayo Clinic Proceedings

81(10)

1361–1367. (See Table 1

page 1362). This article categorizes the psychiatric adverse effects of corticosteroids

listing psychosis

mania

and mood lability as established complications. https://doi.org/10.4065/81.10.1361

The question requires calculating the subcutaneous insulin regimen based on the patient's recent intravenous (IV) insulin requirement and the physician's suggested ratio. The patient's average total daily dose (TDD) from the IV insulin drip was 70 units. The suggested split is 70% for long-acting (basal) insulin and 30% for short-acting (bolus) insulin.

1. Calculate Basal Dose (Insulin Glargine):

TDD × Basal Percentage = 70 units × 0.70 = 49 units.

2. Calculate Total Bolus Dose (Insulin Lispro):

TDD × Bolus Percentage = 70 units × 0.30 = 21 units.

3. Calculate Per-Meal Bolus Dose:

Total Bolus Dose / Number of meals = 21 units / 3 meals = 7 units per meal.

This calculation results in a regimen of 49 units of Insulin Glargine daily and 7 units of Insulin Lispro three times a day with meals.

B. This option represents a 36:64 basal-to-bolus ratio (25 units / 70 units ≈ 36%), which is incorrect.

C. This option represents a 57:43 basal-to-bolus ratio (40 units / 70 units ≈ 57%), which is incorrect.

D. This option represents a 66:34 basal-to-bolus ratio (46 units / 70 units ≈ 66%), which is incorrect.

E. This option represents a 74:26 basal-to-bolus ratio (52 units / 70 units ≈ 74%), which is incorrect.

1. American Diabetes Association Professional Practice Committee. (2023). 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2023. Diabetes Care

46(Supplement1)

S247–S257. https://doi.org/10.2337/dc23-S015. (Section: "Transitioning From Intravenous to Subcutaneous Insulin

" which discusses basing the initial subcutaneous dose on the IV infusion rate over the preceding hours).

2. UCSF Division of Hospital Medicine. (2023). Hyperglycemia & Diabetes. In The UCSF Hospitalist Handbook. University of California

San Francisco. Retrieved from https://hospitalmedicine.ucsf.edu/manual/ch15hyper.html. (Chapter: "Transitioning from Insulin Drip to Subcutaneous Insulin

" which outlines the method of calculating the TDD from the 24-hour IV requirement and then splitting it into basal and bolus components).

3. Kitabchi

A. E.

Umpierrez

G. E.

Miles

J. M.

& Fisher

J. N. (2009). Hyperglycemic crises in adult patients with diabetes. Diabetes Care

32(7)

1335–1343. https://doi.org/10.2337/dc09-9032. (Section: "Transition to Subcutaneous Insulin

" which describes the general principles for initiating a multiple daily injection regimen after DKA resolution).

Thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, are peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists. A well-documented and clinically significant adverse effect of this class is fluid retention. The mechanism involves the upregulation of the epithelial sodium channel (ENaC) in the renal collecting ducts, leading to increased sodium and water reabsorption. This can manifest as peripheral edema, weight gain, and hemodilution. Importantly, this side effect can exacerbate or precipitate congestive heart failure, leading to a boxed warning for this drug class.

A. Bile acid sequestrants primarily cause gastrointestinal side effects, such as constipation and bloating, not systemic fluid retention.

B. GLP-1 agonists are associated with gastrointestinal side effects (nausea, vomiting) and weight loss; they do not cause fluid retention.

D. SGLT2 inhibitors work by promoting urinary glucose excretion, which induces an osmotic diuresis, leading to fluid loss, not retention.

E. Alpha-glucosidase inhibitors act locally in the intestine to delay carbohydrate absorption, causing gastrointestinal side effects like flatulence and diarrhea.

1. American Diabetes Association. (2023). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2023. Diabetes Care

46(Supplement1)

S140–S157. (See Table 9.2

"Drug-Specific and Patient Factors to Consider When Selecting Antihyperglycemic Treatment

" which lists "Edema/Heart Failure" as a side effect for Thiazolidinediones). https://doi.org/10.2337/dc23-S009

2. Katzung

B. G.

& Vanderah

T. W. (2021). Basic & Clinical Pharmacology (15th ed.). McGraw Hill. In Chapter 41

"Pancreatic Hormones & Antidiabetic Drugs

" under the section "Thiazolidinediones

" it states

"The major adverse effect of the thiazolidinediones is fluid retention

which presents as a mild anemia and peripheral edema."

3. Nesto

R. W.

Bell

D.

Bonow

R. O.

Fonseca

V.

et al. (2003). Thiazolidinedione use

fluid retention

and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation

108(23)

2941-2948. (See "Pathophysiology of Fluid Retention" section

which details the renal mechanism). https://doi.org/10.1161/01.CIR.0000103549.88423.75

Sucralfate is an aluminum salt of a sulfated disaccharide. Although its action is primarily local on the gastrointestinal mucosa, a small amount of aluminum is absorbed systemically. In patients with normal kidney function, this absorbed aluminum is excreted by the kidneys. However, in patients with chronic renal failure or those on dialysis, the excretion of aluminum is impaired. Chronic administration of sucralfate in this patient population can lead to the accumulation of aluminum to toxic levels, potentially causing serious adverse effects such as aluminum-induced osteomalacia, adynamic bone disease, and encephalopathy.

B. Bismuth subgallate: This medication contains bismuth, not aluminum. Overuse can lead to bismuth toxicity, which has different clinical manifestations.

C. Docusate sodium: This is a surfactant-type stool softener that does not contain aluminum or affect its systemic absorption or excretion.

D. Lactulose: This is an osmotic laxative used for constipation and hepatic encephalopathy; it has no association with aluminum metabolism.

E. Alginates: Alginates are used for gastroesophageal reflux. While some formulations may be combined with aluminum-containing antacids, alginates themselves are not a source of aluminum.

1. U.S. Food and Drug Administration (FDA). (2013). CARAFATE® (sucralfate) Tablets Prescribing Information. Section: WARNINGS. "In patients with chronic renal failure or those receiving dialysis

aluminum accumulation and toxicity (aluminum osteodystrophy

osteomalacia

encephalopathy) have been described." Available from the FDA website.

2. Brunton

L. L.

Dandan

R.

& Knollmann

B. C. (Eds.). (2017). Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. Chapter 49

Pharmacotherapy of Gastric Acidity

Peptic Ulcers

and Gastroesophageal Reflux Disease

Section: Mucosal Protective Agents. "Because a small amount of Al3+ is absorbed

sucralfate should be used with caution in patients with renal insufficiency

who are at risk for Al3+ overload."

3. DiPiro

J. T.

Yee

G. C.

Posey

L. M.

Haines

S. T.

Nolin

T. D.

& Ellingrod

V. (Eds.). (2020). Pharmacotherapy: A Pathophysiologic Approach (11th ed.). McGraw-Hill Education. Chapter 25

Peptic Ulcer Disease

Section: Mucosal Protective Agents. "Systemic absorption of aluminum is minimal but may be problematic in patients with chronic renal failure because of the risk of accumulation and toxicity."

Intravenous (IV) dextrose is supplied as dextrose monohydrate. While pure, anhydrous carbohydrates provide 4 kcal per gram, the water molecule in dextrose monohydrate adds to the total weight without contributing calories. This "hydration" effectively dilutes the caloric density. Therefore, the standardized caloric value used in all clinical and pharmaceutical calculations for IV dextrose is 3.4 kcal per gram. This value is critical for accurately calculating the energy provided to patients receiving parenteral nutrition.

A. 0.9 kcal/g: This value is incorrect. It may be confused with the percentage concentration of Normal Saline (0.9% sodium chloride), not a caloric value.

B. 1.2 kcal/g: This is an arbitrary and incorrect caloric value for any macronutrient used in parenteral nutrition.

C. 1.5 kcal/g: This is an arbitrary and incorrect caloric value for any macronutrient used in parenteral nutrition.

1. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). (2017). The A.S.P.E.N. Adult Nutrition Support Core Curriculum (3rd ed.). In Chapter 11

Parenteral Nutrition Formulations

it is explicitly stated

"Dextrose monohydrate is the carbohydrate source used in PN solutions in the United States

providing 3.4 kcal/g."

2. Mueller

C. M. (Ed.). (2012). The A.S.P.E.N. Nutrition Support Practice Manual (2nd ed.). American Society for Parenteral and Enteral Nutrition. In Chapter 20

Parenteral Nutrition Formulas

Table 20-1

"Macronutrient Sources for Parenteral Nutrition

" lists Dextrose Monohydrate as providing 3.4 kcal/g.

3. University of Illinois Chicago

College of Pharmacy. (2021). PGY1 Pharmacy Residency Program Educational Materials: Parenteral Nutrition Basics. This university courseware consistently uses 3.4 kcal/g for dextrose in all parenteral nutrition calculation examples and teaching modules.

4. Worthington

P.

Balint

J.

Bechtold

M.

et al. (2017). When is parenteral nutrition appropriate? Journal of Parenteral and Enteral Nutrition

41(3)

324–377. In the section on "Parenteral Nutrition Components

" the caloric value of dextrose is cited as 3.4 kcal/g. https://doi.org/10.1177/0148607117695251

Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose by inducing glucosuria. This mechanism has several physiological consequences that require monitoring. The induced osmotic diuresis can lead to volume depletion, dehydration, and hypotension, making it essential to monitor hydration status (A) and blood pressure (B). As these are antidiabetic medications, blood glucose (C) must be monitored to assess efficacy and the risk of hypoglycemia, especially when used with other glucose-lowering agents. Since SGLT2 inhibitors act directly on the kidneys and can cause an initial decline in the estimated glomerular filtration rate (eGFR), renal function (D) must be assessed at baseline and periodically thereafter. Therefore, all listed parameters are critical for safe and effective therapy.

A. Incorrect because it is an incomplete answer; blood pressure, glucose, and renal function also require monitoring.

B. Incorrect because it is an incomplete answer; hydration status, glucose, and renal function also require monitoring.

C. Incorrect because it is an incomplete answer; hydration status, blood pressure, and renal function also require monitoring.

D. Incorrect because it is an incomplete answer; hydration status, blood pressure, and glucose also require monitoring.

1. U.S. Food and Drug Administration (FDA). (2023). JARDIANCE® (empagliflozin) tablets

for oral use. Prescribing Information. Boehringer Ingelheim Pharmaceuticals

Inc. See Sections 2.2 (Recommended Dosage and Administration - Renal Function)

5.2 (Hypotension)

and 5.4 (Acute Kidney Injury and Impairment in Renal Function). Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/204629s033lbl.pdf

2. American Diabetes Association Professional Practice Committee. (2023). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2023. Diabetes Care

46(Supplement1)

S140–S157. See Table 9.3

which outlines drug-specific and patient factors to consider for SGLT2 inhibitors

including eGFR

volume depletion risk

and blood pressure effects. DOI: https://doi.org/10.2337/dc23-S009

3. Heerspink

H. J. L.

Stefánsson

B. V.

Correa-Rotter

R.

Chertow

G. M.

Greene

T.

Hou

F. F.

Mann

J. F. E.

McMurray

J. J. V.

Lindberg

M.

Rossing

P.

Sjöström

C. D.

Toto

R. D.

& Wheeler

D. C. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine

383(15)

1436–1446. This article discusses the renal and cardiovascular effects of SGLT2 inhibitors

highlighting the importance of monitoring renal function (eGFR) and blood pressure. DOI: https://doi.org/10.1056/NEJMoa2024816

Prevalence is an epidemiological measure that quantifies the proportion of a population with a particular disease or condition at a specific point in time (point prevalence) or over a specified period (period prevalence). It is calculated as the total number of existing cases (both new and pre-existing) divided by the total population. The question's definition of "proportion of people in a population who have a particular disease at a specified point in time" is the exact definition of prevalence.

A. Incidence rate: Measures the rate of new cases of a disease in a population over a specific time period, not the total proportion of existing cases.

C. Mortality rate: Measures the frequency of death in a population, not the proportion of individuals living with a disease.

D. Relative risk: Is a measure of association that compares the risk of disease in an exposed group to the risk in an unexposed group.

E. Odds ratio: Is a measure of association that quantifies the odds of an outcome occurring given an exposure compared to the odds of it occurring without the exposure.

1. Centers for Disease Control and Prevention (CDC). (2012). Principles of Epidemiology in Public Health Practice

Third Edition. Lesson 3: Measures of Risk

Section 2: Frequency Measures. "Prevalence refers to the proportion of persons in a population who have a particular disease or attribute at a specified point in time or over a specified period of time."

2. Boston University School of Public Health. (n.d.). Measures of Disease Frequency. PH717 Module 2. Retrieved from the Boston University website. The module states

"Prevalence is the proportion of a particular population that has the condition of interest at a specified time."

3. Noordzij

M.

Dekker

F. W.

Zoccali

C.

& Jager

K. J. (2010). Measures of disease frequency: prevalence and incidence. Nephron. Clinical practice

115(1)

c17–c20. Page c17

Abstract. "Prevalence is the proportion of a population that has a specific characteristic at a given point in time." https://doi.org/10.1159/000286345

The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol identifies four major statin benefit groups. One of these groups comprises adults aged 21 years and older with primary, severe elevations of low-density lipoprotein cholesterol (LDL-C) at a concentration of 190 mg/dL or greater. For this group, the guideline recommends initiating high-intensity statin therapy to achieve at least a 50% reduction in LDL-C, as this level of hypercholesterolemia confers a high lifetime risk for atherosclerotic cardiovascular disease (ASCVD).

A. ≥ 100 mg/dL: This was a treatment target in older guidelines (ATP III) but is not the 2013 threshold for initiating high-intensity statin therapy based on LDL-C alone.

B. ≥ 130 mg/dL: This was another treatment target in older guidelines, not the specific threshold for this indication in the 2013 guideline.

D. ≥ 200 mg/dL: This value is incorrect; the guideline specifically defines the threshold for severe hypercholesterolemia as ≥190 mg/dL.

E. ≥ 150 mg/dL: This value is incorrect and does not represent a specific threshold for high-intensity statin initiation in the 2013 guideline.

1. Stone

N. J.

Robinson

J. G.

Lichtenstein

A. H.

Bairey Merz

C. N.

Blum

C. B.

Eckel

R. H.

... & Wilson

P. W. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation

129(25suppl2)

S1-S45. https://doi.org/10.1161/01.cir.0000437738.63853.7a (See Table 3: "The 4 Statin Benefit Groups

" page S15

and Recommendation #3

page S18).

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant Gram-negative bacillus. The agent of choice for treating infections caused by this organism is sulfamethoxazole/trimethoprim (TMP-SMX). This recommendation is based on its consistent in vitro activity and established clinical efficacy. S. maltophilia is characteristically and intrinsically resistant to carbapenems (e.g., meropenem) due to the production of two beta-lactamases. While other agents like fluoroquinolones may show some activity, resistance is common and can emerge during therapy, making TMP-SMX the most appropriate and reliable first-line treatment.

A. Meropenem: S. maltophilia is intrinsically resistant to carbapenems due to its production of metallo-β-lactamases (L1) and serine-β-lactamases (L2).

B. Vancomycin: This antibiotic is primarily active against Gram-positive bacteria and has no clinically significant activity against Gram-negative organisms like S. maltophilia.

C. Ciprofloxacin: Resistance rates to fluoroquinolones are high and can develop rapidly during treatment, making it a less reliable option than TMP-SMX.

E. Ampicillin: S. maltophilia is resistant to most penicillins due to the production of beta-lactamases that hydrolyze the antibiotic.

1. Brooke

J. S. (2012). Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clinical Microbiology Reviews

25(1)

2–41. (See page 20

"Therapy

" which states

"Trimethoprim-sulfamethoxazole (SXT) is currently the antimicrobial agent of choice for the treatment of S. maltophilia infections."). DOI: https://doi.org/10.1128/CMR.00019-11

2. Looney

W. J.

Narita

M.

& Mühlemann

K. (2009). Stenotrophomonas maltophilia: an emerging opportunist human pathogen. The Lancet Infectious Diseases

9(5)

312–323. (See page 318

Table 2

which lists Trimethoprim-sulfamethoxazole as the "Drug of choice" and notes intrinsic resistance to carbapenems). DOI: https://doi.org/10.1016/S1473-3099(09)70083-0

3. DiPiro

J. T.

Yee

G. C.

Posey

L. M.

Haines

S. T.

Nolin

T. D.

& Ellingrod

V. L. (2020). Pharmacotherapy: A Pathophysiologic Approach (11th ed.). McGraw-Hill Education. In Chapter 95

"Nosocomial Pneumonia

" the section on Stenotrophomonas maltophilia identifies trimethoprim-sulfamethoxazole as the drug of choice.

The calculation involves two steps. First, determine the total volume of the intravenous fluid (IVF) administered over 24 hours. At a rate of 125 mL/hour, the total volume is 125 mL/hour × 24 hours = 3000 mL. Second, calculate the amount of dextrose in this volume. A "Dextrose 5%" solution means it contains 5 grams of dextrose per 100 mL of solution (% w/v). Using this concentration, the total amount of dextrose is (5 g / 100 mL) × 3000 mL = 150 grams. The potassium chloride content is not relevant to this specific question.

A. 300gm: This would be the correct amount if the solution was Dextrose 10%, not 5%.

B. 500gm: This is an incorrect calculation, possibly confusing the percentage with the final amount in grams.

C. 50gm: This represents the amount of dextrose in only 1000 mL (1 L) of the solution, not the total 24-hour volume of 3000 mL.

E. 200gm: This is a mathematical error and does not correspond to the given concentration and infusion rate.

1. Allen

L. V.

Jr. (2018). Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (11th ed.). Wolters Kluwer. Chapter 6

"Pharmaceutical Calculations

" Section on Percentage Strength

p. 115. This section defines percentage weight-in-volume (% w/v) as grams of a constituent in 100 mL of solution.

2. University of Washington School of Pharmacy. (n.d.). Pharm 558: Pharmaceutical Calculations - Intravenous Flow Rates. Course materials. These materials detail the standard method for calculating the total amount of a drug infused over a specific period by first determining the total volume (Rate × Time) and then multiplying by the drug concentration.

3. Zatz

J. L.

& Teixeira

M. G. (2005). Pharmaceutical Calculations (4th ed.). Wiley-Interscience. Chapter 5

"Percentage

Ratio Strength

and Other Expressions of Concentration

" pp. 67-69. This chapter provides examples for calculating the quantity of an active ingredient in a specified volume of a liquid when the concentration is expressed as a percentage.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert their antihyperglycemic effect by directly targeting the kidneys. They selectively block the SGLT2 protein located in the proximal convoluted tubules. This inhibition prevents the reabsorption of filtered glucose from the tubular fluid back into the bloodstream. Consequently, excess glucose is excreted in the urine (glucosuria), leading to a reduction in plasma glucose concentrations. This mechanism of action is independent of insulin secretion or sensitivity, focusing solely on renal glucose handling.

A. Sulfonylureas: Act primarily on the pancreatic beta cells to stimulate insulin secretion.

B. Alpha-Glucosidase Inhibitors: Work in the brush border of the small intestine to delay carbohydrate absorption.

C. DPP4 Inhibitors: Prevent the breakdown of incretin hormones (like GLP-1), which act on the pancreas to enhance glucose-dependent insulin secretion.

D. Glucagon-like peptide-1 receptor agonists: Mimic incretin hormones, acting on the pancreas, brain, and gastrointestinal tract.

E. Thiazolidinediones: Increase insulin sensitivity in peripheral tissues, primarily adipose tissue, skeletal muscle, and the liver.

F. Biguanide: Primarily decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues.

1. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care

47(Supplement1)

S158–S178. (See Table 9.3

"Mechanisms of action of noninsulin glucose-lowering medications for type 2 diabetes"). https://doi.org/10.2337/dc24-S009

2. DeFronzo

R. A.

Norton

L.

& Abdul-Ghani

M. (2017). Renal

metabolic and cardiovascular considerations of SGLT2 inhibitors. Nature Reviews Nephrology

13(1)

11–26. (See Section: "Mechanism of action of SGLT2 inhibitors

" p. 12). https://doi.org/10.1038/nrneph.2016.170

3. Brunton

L. L.

Knollmann

B. C.

& Hilal-Dandan

R. (Eds.). (2018). Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. (See Chapter 48

Section: "Sodium-Glucose Cotransporter 2 Inhibitors").

The protamine dose is based on the amount of active heparin in the body, which is calculated by considering the heparin administered in the last 2-3 hours and its half-life.

1. Calculate heparin rate: 13 mL/hr × 50 units/mL = 650 units/hr.

2. Calculate heparin to be neutralized:

From the most recent hour: 650 units (100% active).

From the previous hour (1-2 hours ago): 650 units / 2 = 325 units (50% active, as one half-life of 60 minutes has passed).

3. Total active heparin: 650 units + 325 units = 975 units.

4. Calculate protamine dose: 975 units / (100 units/mg) = 9.75 mg.

The closest answer is 9.7 mg.

A. 5mg: This dose is too low and would result from a significant miscalculation, leading to inadequate heparin reversal.

B. 10mg: This is a rounded value and less precise than the calculated dose based on the provided pharmacokinetic parameters.

C. 7mg: This dose is incorrect and may result from only partially accounting for the heparin administered in the last hour.

D. 13mg: This is incorrect as it reverses the total heparin given over 2 hours (1300 units) without accounting for the 60-minute half-life.

1. University of Illinois Chicago (UIC) College of Pharmacy

Drug Information Group. (2019). FAQ: What is the appropriate dose of protamine for the reversal of unfractionated heparin (UFH)? This document outlines the standard calculation method: "The dose of protamine is dependent on the amount of heparin given in the previous 2 to 3 hours... For continuous infusions

100% of the heparin administered in the last hour

50% of the heparin administered in the hour prior

and 25% of the heparin administered in the hour before that should be reversed."

2. Weitz

J. I.

& Weitz

J. I. (2018). Blood Coagulation and Anticoagulant

Fibrinolytic

and Antiplatelet Drugs. In L. L. Brunton

R. Hilal-Dandan

& B. C. Knollmann (Eds.)

Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.

Chapter 32). McGraw-Hill Education. The text describes protamine dosing based on the principle that 1 mg neutralizes approximately 100 units of heparin

emphasizing that the dose must be adjusted for time elapsed due to heparin's short half-life.

3. Hirsh

J.

Bauer

K. A.

& Guyatt

G. H. (2008). Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest

133(6suppl)

141S-159S. https://doi.org/10.1378/chest.08-0689. Section 2.3.3 discusses heparin's pharmacokinetics (half-life of 30-90 minutes) and Section 4.3 covers management of bleeding

where protamine dosing is based on the amount of heparin recently infused.

Adalat is a brand name for the drug nifedipine. Nifedipine is a dihydropyridine calcium channel blocker used primarily for the management of hypertension and chronic stable angina. It works by inhibiting the influx of calcium ions into vascular smooth muscle and myocardial cells, leading to peripheral and coronary artery vasodilation. This vasodilation reduces peripheral resistance, lowers blood pressure, and increases coronary blood flow, thereby alleviating angina symptoms. The most common formulation is an extended-release tablet, such as Adalat CC.

B. Adalimumab is the active ingredient in Humira, a biologic medication used to treat various autoimmune diseases.

C. Digoxin is the active ingredient in Lanoxin, a cardiac glycoside used for heart failure and atrial fibrillation.

D. Simvastatin is the active ingredient in Zocor, an HMG-CoA reductase inhibitor used to lower cholesterol levels.

1. U.S. Food and Drug Administration (FDA). (2019). ADALAT CC (nifedipine) extended-release tablets

for oral use. Prescribing Information. Application No. N019955. Section 11: DESCRIPTION. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/019955s064lbl.pdf

2. Whalen

K.

Finkel

R.

& Panavelil

T. A. (2018). Lippincott Illustrated Reviews: Pharmacology (7th ed.). Wolters Kluwer. Chapter 21: Calcium Channel Blockers

p. 275. (This text is standard courseware in many university pharmacy programs).

3. Katzung

B. G.

& Vanderah

T. W. (2021). Basic & Clinical Pharmacology (15th ed.). McGraw-Hill Education. Chapter 12: Vasodilators & the Treatment of Angina Pectoris

Table 12-1. (This is a foundational textbook in pharmacology curricula at reputable universities).

The calculation requires three steps. First, determine the concentration of the vasopressin solution: 40 units divided by 100 mL equals 0.4 units/mL. Second, convert the ordered dose rate from minutes to hours: 0.03 units/minute multiplied by 60 minutes/hour equals 1.8 units/hour. Finally, calculate the infusion rate in mL/hr by dividing the hourly dose by the concentration: (1.8 units/hr) / (0.4 units/mL) = 4.5 mL/hr. This is the correct rate to deliver the prescribed dose.

A. 4.0 ml/hr: This rate is incorrect and would result in underdosing the patient. It may stem from a miscalculation of the hourly dose or the drug concentration.

B. 4.9ml/hr: This is a calculation error. This rate does not align with the prescribed dose and available concentration.

D. 3.5ml/hr: This is a calculation error. This rate would deliver an insufficient amount of medication to the patient.

E. 6ml/hr: This rate is incorrect and would result in overdosing the patient. It would be the correct rate for a dose of 0.04 units/min, not the prescribed 0.03 units/min.

1. University of Washington

School of Pharmacy. (n.d.). Pharmaceutical Calculations: Infusion Rate Calculations. In PHARM 559 Course Materials. This type of university courseware outlines the standard dimensional analysis method for calculating intravenous infusion rates. The formula used is Rate (mL/hr) = [Dose (units/hr)] / [Concentration (units/mL)].

2. Evans

L.

et al. (2021). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine

49(11)

e1063-e1143. In Recommendation 31

the guidelines state

"For adults with septic shock on norepinephrine with inadequate mean arterial pressure levels

we suggest adding vasopressin (up to 0.03 U/min)." This peer-reviewed source validates the clinical appropriateness of the dose used in the question. (DOI: 10.1097/CCM.0000000000005337)

3. Stoklosa

M. J.

& Ansel

H. C. (2012). Pharmaceutical Calculations (14th ed.). Lippincott Williams & Wilkins. Chapter 11

"Isotonicity

Osmolality

and Intravenous Infusion Calculations

" provides the foundational principles and formulas for determining the rate of flow for intravenous infusions based on the volume of solution

quantity of drug

and desired dose.

The patient's result of 156 mg/dL on the 1-hour, 50 g glucose challenge test (GCT) is considered a positive screen for gestational diabetes mellitus (GDM), as it exceeds the commonly used thresholds of 130-140 mg/dL. A positive GCT is not diagnostic but indicates the need for further testing. The standard, accepted next step in the two-step screening approach is to perform a confirmatory 3-hour, 100 g oral glucose tolerance test (OGTT). A diagnosis of GDM is made based on the results of this second test. Initiating treatment or dietary changes before a formal diagnosis is premature.

A. Repeat the 50 g oral glucose challenge: The initial screening test was positive; repeating it is redundant and delays the necessary diagnostic evaluation.

C. Advise the patient to follow an American Diabetic Association diet plan: Dietary intervention is a primary treatment for GDM, but it should only be initiated after a confirmed diagnosis from the 3-hour OGTT.

D. Begin insulin treatment: Insulin is a pharmacological treatment for GDM that is not controlled by diet and exercise. It is inappropriate without a confirmed diagnosis.

E. Order a fetal ultrasound examination: While fetal ultrasounds are important for monitoring fetal growth in pregnancies complicated by GDM, it is not the next step for diagnosing the condition.

1. American College of Obstetricians and Gynecologists (ACOG). (2018). ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics & Gynecology

131(2)

e49-e64. (Reaffirmed 2021). In the section "Screening and Diagnosis

" the bulletin outlines the two-step approach

stating that a positive 50-g screen should be followed by a 3-hour 100-g OGTT for diagnosis. DOI: 10.1097/AOG.0000000000002501

2. American Diabetes Association Professional Practice Committee. (2023). 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2023. Diabetes Care

46(Suppl 1)

S254–S266. Section 15.3

"Screening for and Diagnosis of GDM

" describes the two-step strategy where a positive 1-hour 50-g screen is followed by a 3-hour 100-g OGTT. DOI: 10.2337/dc23-S015

3. Landon

M. B.

& Gabbe

S. G. (2011). Gestational diabetes mellitus. Obstetrics & Gynecology

118(6)

1379–1393. This peer-reviewed article discusses the screening protocols

explicitly stating the progression from a 50-g glucose challenge to a 100-g oral glucose tolerance test for diagnosis. DOI: 10.1097/AOG.0b013e3182364d39

The patient's clinical presentation is characteristic of acute viral rhinosinusitis, commonly known as the common cold. The key indicators are the short duration of symptoms (6 days), the nature of the discharge (thin, clear rhinorrhea), the absence of high fever, and the fact that the symptoms are improving. Acute bacterial rhinosinusitis is generally suspected only when symptoms persist for 10 days or more without any improvement, are severe at onset (e.g., fever ≥39°C, purulent discharge), or worsen after a period of initial improvement ("double sickening"). Since this patient's condition is mild and resolving, a viral etiology is the most probable cause.

A. Streptococcus pneumoniae is a leading cause of bacterial sinusitis, which is inconsistent with the patient's improving, non-severe symptoms.

C. Moraxella catarrhalis is a common bacterial pathogen in sinusitis, but the clinical picture does not support a bacterial infection.

D. Haemophilus influenzae is a frequent cause of bacterial sinusitis; however, the patient's presentation points to a viral, self-limiting illness.

E. Staphylococcus aureus is a less common cause of community-acquired bacterial sinusitis and is not suggested by these mild, resolving symptoms.

1. Chow

A. W.

Benninger

M. S.

Brook

I.

et al. (2012). IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clinical Infectious Diseases

54(8)

e72–e112. (See Table 2

page e76

which outlines criteria for distinguishing viral from bacterial rhinosinusitis. Viral rhinosinusitis is characterized by a duration of less than 10 days with symptoms that are not worsening). https://doi.org/10.1093/cid/cis370

2. Rosenfeld

R. M.

Piccirillo

J. F.

Chandrasekhar

S. S.

et al. (2015). Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery

152(2suppl)

S1–S39. (See Section 2

"Distinguishing Viral vs. Bacterial Sinusitis

" which states that viral rhinosinusitis is far more common and typically resolves or improves within 10 days). https://doi.org/10.1177/0194599815572097

3. DiPiro

J. T.

Yee

G. C.

Posey

L. M.

Haines

S. T.

Nolin

T. D.

& Ellingrod

V. (2020). Pharmacotherapy: A Pathophysiologic Approach (11th ed.). McGraw-Hill. In Chapter 88

"Upper Respiratory Tract Infections

" the text clarifies that the vast majority of acute rhinosinusitis cases are caused by viruses and are self-limiting

with symptoms peaking at 3-6 days and resolving by day 10.

Systemic Lupus Erythematosus (Lupus) is a classic example of a type III hypersensitivity reaction. This condition is characterized by the formation of autoantibodies against nuclear antigens. These antibodies bind to the antigens, forming immune complexes that circulate and deposit in various tissues, such as the kidneys, skin, and joints. The deposition of these complexes activates the complement system and recruits inflammatory cells, leading to tissue damage and the systemic manifestations of the disease.

B. Graves disease: This is a type II hypersensitivity reaction, where autoantibodies stimulate the TSH receptor on thyroid cells, causing hyperthyroidism.

C. Hashimoto’s thyroiditis: This is primarily a type IV (T-cell mediated) hypersensitivity reaction, leading to the destruction of thyroid tissue by cytotoxic T-lymphocytes.

D. Allergic rhinitis: This is a type I (IgE-mediated) hypersensitivity reaction, where allergens trigger the release of histamine from mast cells.

E. Myasthenia gravis: This is a type II hypersensitivity reaction, where autoantibodies block or destroy acetylcholine receptors at the neuromuscular junction.

1. Abbas

A. K.

Lichtman

A. H.

& Pillai

S. (2020). Cellular and Molecular Immunology (10th ed.). Elsevier.

For Lupus (Type III): Chapter 19

"Diseases Caused by Immune Responses: Hypersensitivity and Autoimmunity

" Section on "Immune Complex-Mediated Diseases (Type III Hypersensitivity)

" states

"Systemic lupus erythematosus (SLE) is the prototypic systemic immune complex–mediated disease."

For Graves disease and Myasthenia gravis (Type II): Chapter 19

Section on "Antibody-Mediated Diseases (Type II Hypersensitivity)

" lists Graves' disease and myasthenia gravis as examples of diseases caused by antibodies against cell surface receptors.

For Hashimoto's thyroiditis (Type IV): Chapter 19

Section on "T Lymphocyte-Mediated Diseases (Type IV Hypersensitivity)

" describes Hashimoto's thyroiditis as an autoimmune disease resulting from T-cell mediated destruction of thyroid epithelial cells.

2. Justiz Vaillant

A. A.

& Zulfiqar

H. (2023). Hypersensitivity Reactions. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK560561/

Table 1

"Gell and Coombs Classification of Hypersensitivity Reactions

" explicitly lists Systemic Lupus Erythematosus under Type III

Allergic Rhinitis under Type I

Graves' Disease and Myasthenia Gravis under Type II

and Hashimoto's Thyroiditis under Type IV.

3. Stanford University School of Medicine. (n.d.). Immunology Course (IMM 205/206) Lecture Notes: Hypersensitivity Reactions.

In lectures covering the Gell and Coombs classification

Lupus is consistently presented as the archetypal Type III reaction due to immune complex deposition in tissues like the glomeruli. Graves' disease and Myasthenia gravis are used as primary examples of Type II receptor-targeting antibody-mediated disease.

Valproic acid has a black box warning for life-threatening pancreatitis, which can occur at any time during therapy in both children and adults. This is a rare but serious adverse effect that can progress rapidly and be fatal. Patients should be counseled to report any signs or symptoms of pancreatitis, such as severe abdominal pain, nausea, vomiting, or anorexia, to their healthcare provider immediately. The drug should be discontinued if pancreatitis is diagnosed.

A. Gingival hyperplasia is a classic and common side effect associated with phenytoin, not valproic acid.

C. Kidney stones (nephrolithiasis) are a known adverse effect of other antiepileptic drugs like topiramate and zonisamide.

D. Valproic acid is commonly associated with significant weight gain, which is often a reason for non-adherence.

E. Euphoria is not a recognized side effect of valproic acid; sedation and dizziness are more common CNS effects.

1. U.S. Food and Drug Administration (FDA). (2018). DEPAKOTE (divalproex sodium) delayed-release tablets

for oral use. Highlights of Prescribing Information. Section: WARNINGS AND PRECAUTIONS

5.2 Pancreatitis. Retrieved from the FDA database. (This official vendor documentation explicitly lists pancreatitis as a boxed warning).

2. Zaccara

G.

Franciotta

D.

& Perucca

E. (2007). Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia

48(7)

1223–1244. https://doi.org/10.1111/j.1528-1167.2007.01041.x (Table 2 on page 1228 lists pancreatitis as a rare

life-threatening idiosyncratic reaction to valproate).

3. McNamara

J. O. (2018). Pharmacotherapy of the Epilepsies. In L. L. Brunton

R. Hilal-Dandan

& B. C. Knollmann (Eds.)

Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. Chapter 17

Section: Valproate

Subsection: Adverse Effects. (This standard academic textbook

used in university curricula

details pancreatitis as a serious idiosyncratic toxicity of valproate).

The patient's clinical presentation of a unilateral, throbbing headache associated with photophobia and nausea is characteristic of a migraine. The question asks for an abortive therapy, which is a medication taken to stop a migraine attack after it has started. Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist (a "triptan") and is a first-line abortive treatment for moderate-to-severe migraine attacks. It works by causing vasoconstriction of cranial arteries and inhibiting the release of vasoactive neuropeptides. The other medications listed are used for migraine prophylaxis (prevention), not for treating an acute attack.

B. Gabapentin: This is an anticonvulsant medication sometimes used off-label for migraine prophylaxis, not for aborting an acute attack.

C. Amitriptyline: This is a tricyclic antidepressant that is established as an effective agent for migraine prophylaxis.

D. Propranolol: This beta-blocker is a first-line, evidence-based medication used for the prophylaxis of episodic migraines.

E. Diltiazem: This calcium channel blocker is not a standard first-line therapy for either abortive or prophylactic treatment of migraine.

1. Marmura

M. J.

Silberstein

S. D.

& Schwedt

T. J. (2015). The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache: The Journal of Head and Face Pain

55(1)

3–20. (In Table 2

"Triptans

" including sumatriptan

are listed with a Grade A recommendation as effective for acute migraine treatment). https://doi.org/10.1111/head.12499

2. Silberstein

S. D.

Holland

S.

Lipton

R. B.

& Dodick

D. W. (2012). Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology

78(17)

1337–1345. (In Table 2

propranolol and amitriptyline are listed as having Level A evidence for migraine prevention. Gabapentin is mentioned as having inadequate evidence to support its use). https://doi.org/10.1212/WNL.0b013e3182535d20

3. VanderPluym

J. H.

Halker Singh

R. B.

& Urtecho

M. (2021). Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA

325(23)

2357–2369. (This meta-analysis confirms that triptans are highly effective for acute migraine treatment

specifically for pain freedom at 2 hours). https://doi.org/10.1001/jama.2021.7939

4. University of California

San Francisco (UCSF) Headache Center. (n.d.). Medications for Migraine and Headache. UCSF Department of Neurology. (This educational resource clearly distinguishes between "Abortive Medications" like triptans and "Preventive Medications" like beta-blockers

antidepressants

and anti-seizure drugs). Retrieved from https://headache.ucsf.edu/medications-migraine-and-headache (Section: "Abortive Medications" and "Preventive Medications").